1. PO-1166 Treatment patterns and efficacy of durvalumab maintenance after CRT in real-world NSCLC patients. (August 2021) Authors: Taugner, J.; Käsmann, L.; Eze, C.; Flörsch, B.; Guggenberger, J.; Tufman, A.; Reinmuth, N.; Duell, T.; Belka, C.; Manapov, F. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S968 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO-1252 Treatment patterns and prognosis in inoperable stage III NSCLC treated with concurrent CRT +/- ICI. (May 2022) Authors: Flörsch, B.; Taugner, J.; Käsmann, L.; Kenndoff, S.; Guggenberger, J.; Tufman, A.; Reinmuth, N.; Duell, T.; Belka, C.; Eze, C.; Manapov, F. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S1056 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced non-small-cell lung cancer. (2015) Authors: Duell, T.; Kappler, S.; Knöferl, B.; Schuster, T.; Hochhaus, J.; Morresi-Hauf, A.; Huber, RM.; Tufman, A.; Zietemann, V. Journal: Cancer treatment communications Issue: Volume 4(2016)Supplement 1 Page Start: 106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗